Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 7, 2008 - Issue 5
Submit an article Journal homepage
2,592
Views
106
CrossRef citations to date
0
Altmetric
Review

Drug-induced serotonin syndrome: a review

Christina Sun-Edelstein New York Headache Center, New York, NY, USA
, MD,
Stewart J Tepper Center for Headache and Pain, Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA
, MD &
Robert E Shapiro University of Vermont College of Medicine, Department of Neurology, Given C219B, 89 Beaumont Ave, Burlington, VT, USA +1 802 656 1480; +1 802 656 5844; [email protected]
, MD PhD
Pages 587-596 | Published online: 01 Sep 2008

Bibliography

  • Oates JA, Sjostrand U. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology 1960;10:1076-8
  • Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112-20
  • Gillman PK. Serotonin syndrome: history and risk. Fundam Clin Pharmacol 1998;12:482-91
  • Gillman PK. A review of serotonin toxicity data: implication for the mechanisms of antidepressant drug action. Biol Psychiatry 2006;59:1046-51
  • Dunkley EJC, Isbister GK, Sibbritt D, et al. The Hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. Q J Med 2003;96:635-42
  • Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13
  • Isbister GK, Dawson AH, Whyte IM. Comment: serotonin syndrome induced by fluvoxamine and mirtazapine. Ann Pharmacother 2001;35:1674-5
  • Isbister GK, Downes F, Whyte IM. Olanzapine and serotonin toxicity. Psyshiatry Clin Neurosci 2003;57:244
  • Evans RW. The FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and Triptans: an analysis of the 29 case reports. Medscape 2007;9:48
  • Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract 1999;49:871-4
  • Watson WA, Litovitz TL, Rodgers GC Jr, et al. Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003;21:353-421
  • Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004;42:277-85
  • Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract 1999;49:871-4
  • Marley E, Wozniak KM. Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine re-uptake inhibitors. Psychol Med 1983;13:735-49
  • Marley E, Wozniak KM. Interactions between relatively selective amine oxidase (MAOI) inhibitors and clomipramine. Brit J Pharmacol 1983;78:21
  • Marley E, Wozniak KM. Interactions of a non-selective monoamine oxidase inhibitor, phenelzine, with inhibitors of 5-hydroxytryptamine, dopamine or noradrenaline re-uptake. J Psychiatr Res 1984;18:173-89
  • Marley E, Wozniak KM. Interactions of non-selective monoamine oxidase inhibitors, tranylcypromine and nialamide, with inhibitors of 5-hydroxytryptamine, dopamine and noradrenaline re-uptake. J Psychiatr Res 1984;18:191-203
  • Marley E, Wozniak KM. Interactions between relatively selective monoamine oxidase inhibitors and an inhibitor of 5-hydroxytryptamine re-uptake, clomipramine. J Psychiatr Res 1985;19:597-608
  • Nisijima K, Shioda K, Yoshino T, et al. Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome. Neurochem Int 2003;43(2):155-64
  • Nisijima K, Yoshino T, Ishiguro T. Risperidone counteracts lethality in an animal model of the serotonin syndrome. Psychopharmacology (Berl) 2000;150(1):9-14
  • Gillman PK. Available from: www.psychotropical.com/Serotonin.Toxicity.doc (or Serotonin toxicity, serotonin syndrome: update, overview, and analysis, 2007. Available from: http://www.psychotropical.com/1_st_intro.shtml)
  • Saper CB. Brainstem modulation of sensation, movement, and consciousness. In: Kandel ER, Schwartz JH, Jessell TM, editors, Principles of neural science. 4th edition. McGraw-Hill: New York; 2000. p. 896
  • Gillman PK, Whyte IM. Serotonin syndrome. In: Haddad P, Dursun S, Deakin B, editors, Adverse syndromes and psychiatric drugs. Oxford University Press: Oxford; 2004. p. 37-49
  • Van Oekelen D, Megens A, Meert T, et al. Functional study of rat 5-HT2A receptors using antisense oligonucleotides. J Neurochem 2003;85:1087-100
  • Isbister GK. Serotonin syndrome, mydriasis, and cyproheptadine. Ann Pharmacother 2001;35:1672-3
  • Nisijima K, Shioda K, Yoshino T, et al. Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. Pharmacopsychiatry 2004;37:57-62
  • Isbister GK, Whyte IM. Serotonin toxicity and malignant hyperthermia: role of 5-HT2 receptors. Br J Anaesth 2002;88:603-4
  • Nisijima K, Yoshino T, Yui K, Katoh S. Potent serotonin (5-HT2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res 2001;890:23-31
  • Whyte IM. Serotonin toxicity (syndrome). In: Dart RC, editor, Medical toxicology. Lippinicott, Williams &Wilkins: Baltimore; 2004. p. 103-6
  • Isbister GK, Buckley NA. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clinl Neuropharmacol 2005;28(5):205-14
  • Gillman PK. Making sense of serotonin toxicity reports. A comment on Chopra et al. World J Biol Psychiatry 2004;5:166-7
  • Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol 1999;13(1):100-9
  • Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 2005;95:434-41
  • Gillman PK. Ecstasy, serotonin syndrome and the treatment of hyperpyrexia. Med J Aust 1997;167:109-11
  • Snider SR, Hutt C, Stein B, Fahn S. Increase in brain serotonin produced by bromocriptin. Neurosci Lett 1975;1:237-41
  • Newman-Tancredi A, Cussac D, Quentric Y, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 2002;815-22
  • Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 1997;17:208-21
  • Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology 1995;45:219-23
  • Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome: presentation of 2 cases and review of the literature. Medicine 2000;79:201-9
  • Hegerl U, Bottlender R, Gallinat J, et al. The serotonin syndrome scale: first results on validity. Eur Arch Psychiatry Clin Neurosci 1998;248:96-103
  • Isbister GK, Hackett LP, Dawson AH, et al. Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. Br J Clin Pharmacol 2003;56:441-50
  • Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 2003;96(5):369-74
  • Buckley NA, Faunce TA. ‘Atypical'antidepressants in overdose: clinical considerations with respect to safety. Drug Saf 2003;26:539-51
  • Lau GT, Horowitz BZ. Sertraline overdose. Acad Emerg Med 1996;3:132-6
  • Gillman PK, Hodgens S. Serotonin syndrome following SSRI mono-therapy. Hum Psychopharmacol Clin Exp 1998;13:525-6
  • Whyte IM, Dawson AH. Relative toxicity of venlafaxine and serotonin specific reuptake inhibitors in overdose. Proc Australas Soc Clin Exp Pharmacol Toxicol 2000;8:17
  • Bamigbade TA, Davidson C, Langford RM, Stamford JA. Actions of tramadol, is enantiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nuclus. Br J Anaesth 1997;79:352-6
  • Beique JC, Lavoie N, Demontigny C, Debonnel G. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol 1998;349:129-32
  • Gillman PK. Mocolebemide and the risk of serotonin toxicity (or serotonin syndrome). CNS Drug Rev 2004;10:83-5
  • Whyte IM, Buckley NA. Relative toxicity and resource utilization in antidepressant self poisoning: tricyclics vs specific serotonin reuptake inhibitors. Proc Australas Soc Clin Exp Pharmacol Toxicol 1995;2:103
  • Amsterdam JD, Garcia-Espana F, Rosenzqeig M. Clomipramine augmentation in treatment-resistant depression. Depress Anxiety 1997;5:84-90
  • Oefele KV, Grohmann R, Ruther E. Adverse drug reactions in combined tricyclic and MAOI therapy. Pharmacopsychiatry 1986;19:243-4
  • Dawson AH. Cyclic antidepressant drugs. In: Dart RC, editor, Medical toxicology. Lippinicott, Williams & Wilkins: Baltimore; 2004. p. 834-43
  • Gillman PK. Amitriptyline: dual-action antidepressant? J Clin Psychiatry 2003;64:1391
  • Whyte IM. Other antidepressants. In: Dart RC, editor, Medical toxicology. Lippinicott, Williams & Wilkins: Baltimore; 2004. p. 851-61
  • Whyte IM. Monoamine oxidase inhibitors. In: Dart RC, editor, Medical toxicology. Lippinicott, Williams & Wilkins: Baltimore; 2004. p. 823-34
  • Hawley CJ, Quick SJ, Ratnam S, et al. Safety and tolerability of combined treatment with moclobemide and SSRIs: a preliminary study. Eur Neuropsychopharmacol 1996;6(3):s127
  • Hawley CJ, Quick SJ, Ratnam S, et al. Safety and tolerability of combined treatment with moclobemide and SSRIs - a systematic study of 50 patients. Int Clin Psychopharmacol 1996;11:187-91
  • Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev 2003;9:97-140
  • Debattista C, Sofuoglu M, Schatzberg AF. Serotonergic synergism: the risks and benefits of combing the selevtive serotonin reuptake inhibitors with other serotonergic drugs. Biol Psychiatry 1998;44:341-7
  • Palmer H. Potentiation of pethidine. Br Med J 1960;2:944
  • Reid NCRW, Jones D. Pethidine and phenelzine. Br Med J 1962;1:408
  • Shee JC. Dangerous potentiation of pethidine by iproniazid and its treatment. Br J Med 1960;2:507-9
  • Papp C, Benaim S. Toxic effects of iproniazid in a patient with angina. Br Med J 1958;2:1070-2
  • Baele P, Kestens-Servaye Y, Goenen M. MAOI and cardiac surgery. Can J Anaesth 1993;40:579-80
  • Bowdle TA. Adverse effects of opioid agonists and agonist-antagonists in anaesthesia. Drug Saf 1998;19:173-89
  • Stack CG, Rogers P, Linter SPK. Monoamine oxidase inhibitors and anaesthesia. Br J Anaesth 1988;60:222-7
  • Noble WH, Baker A. MAO inhibitors and coronary artery surgery: a patient death. Can J Anaesth 1992;39:1061-6
  • Roy S, Fortier LP. Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafaxine. Can J Anaesth 2003;50:32-5
  • Ure KS, Gillies MA, James KS. Safe use of remifentanil in a patient treated with the monoamine oxidase inhibitor phenelzine. Br J Anaesth 2000;84:414-6
  • Feinberg SS. Combining stimulants with monamine oxidase inhibitors: a review of uses and one possible additional indication. J Clin Psychiatry 2004;65:1520-4
  • Rothman RB, Baumann MH. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 2003;479:23-40
  • Shapiro RE, Tepper SJ. The serotonin syndrome, triptans, and the potential for drug-drug interactions. Headache 2007;47:266-9
  • Soldin OP, Tonning JM. Serotonin syndrome associated with triptan monotherapy. NEJM 2008;358:2185-6
  • Goodman & Gilman's the pharmacological basis of therapeutics. 11th edition. In: Brunton LL, editor, McGraw-Hill: New York; 2006
  • Adan-Manes J, Novalbos J, Lopez-Rodriguez R, et al. Lithium and venlafaxine interaction: a case of serotonin syndrome. J Clin Pharm Ther 2006;31:397-400
  • Mekler G, Woggon B. A case of serotonin syndrome caused by venlafaxine and lithium. Pharmacopsychiatry 1997;30:272-3
  • Isbister GK, Whyte IM. Adverse reactions to mirtazapine are unlikely to be serotonin toxicity. Clinical Neuropharmacology 2003;26:287-8
  • Ubogu EE, Katirgi B. Adverse reactions to mirtazapine are unlikely to be serotonin toxicity and Mirtazapine: unable to induce serotonin toxicity? Clin Neuropharmacol 2003;26(2):289-90
  • Gillman PK. Mirtazapine: unable to induce serotonin toxicity? Clin Neuropharmacol 2003;26:288-9
  • Schaper E. Suicide with mirtazapine-hardly possible. J Toxicol Clin Toxicol 2002;40:343-4
  • Hick JL, Smith SW, Lynch MT. Metabolic acidosis in restraint-associated cardiac arrest: a case series. Acad Emerg Med 1999;6:239-45
  • Nisijima K, Shioda K, Yoshino T, et al. Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome. Neurochem Int 2003;43:155-64
  • Kapur S, Zipursky RB, Jones C, et al. Cyproheptadine: a potent in vivo serotonin antagonist. Am J Pschiatry 1997;154:884
  • Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519-26
  • Whyte IM, Dawson AH. Redefining the serotonin syndrome. J Toxicol Clin Toxicol 2002;40:668-9
  • Boddy R, Ali R, Dowsett R. Use of sublingual olanzapine in serotonin syndrome [abstract]. J Toxicol Clin Toxicol 2004;42:725

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.